Form 4 for AMGN Amgen
Accepted 2025-02-13 00:00:00 ET · period of report 2025-02-11 · accession 0001127602-25-004776 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-13 | 2025-02-11 | AMGN | Gordon Murdo | EVP, Gbl Commercial Ops | S - Sale | $294.79 | -8,771 | 44.2K | -17% | -$2.59M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-11 | S | D | 8,771 | $294.79 | 44,186 | D | — | — | (F1) The price reported is an average price. The prices ranged from $294.6101 to $294.885 per share. Full information regarding the number of shares purchased at each separate price within the range set forth is available upon request by the SEC staff, the issuer or a security holder of the issuer. (F2) These shares include 773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |